Related Experiment Video
Updated: Jul 2, 2025
09:33
Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
Cytomegalovirus Infection and Alzheimer's Disease: A Meta-Analysis
1Yiqiang Zhan, Department of Epidemiology, School of Public Health (Shenzhen), Sun Yat-Sen University, Shenzhen, China; Tel: 0755-23260106;
The Journal of Prevention of Alzheimer'S Disease
|February 20, 2024
Summary
Cytomegalovirus (CMV) infection shows a potential link to Alzheimer's disease (AD) risk, particularly in East Asian populations and specific study designs. Further research is needed to confirm these associations.
Area of Science:
- Neuroscience
- Infectious Diseases
- Epidemiology
Background:
- The link between cytomegalovirus (CMV) infection and Alzheimer's disease (AD) is not well-established, with existing evidence being scarce and inconsistent.
- Understanding potential infectious triggers for AD is crucial for developing preventative strategies.
Conclusions:
- The association between CMV infection and AD risk is heterogeneous, varying across different populations and study methodologies.
- Larger, multi-ethnic studies are required to clarify the complex relationship between CMV infection and Alzheimer's disease.
Related Concept Videos
01:26Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
01:22Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189